The successful use of a selective LOXL2 pharmacologic inhibitor to address oral cancer in two in vivo mouse models provides pre-clinical evidence that supports the notion that similar inhibitors may have therapeutic potential against oral cancer. Here, LOXL2 is linked to lip and oral cavity carcinoma.